Diana Ernst, RPh

Most Recent Articles by Diana Ernst, RPh

Updated Contraindications, Dosing for Gaucher Disease Treatment Cerdelga

Updated Contraindications, Dosing for Gaucher Disease Treatment Cerdelga

By

Cerdelga is indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers, intermediate metabolizers, or poor metabolizers as detected by an FDA-cleared test.

DMD Treatment Gets Orphan Drug, Rare Pediatric Disease Designations

DMD Treatment Gets Orphan Drug, Rare Pediatric Disease Designations

By

DMD is predominately caused by out-of-frame deletions in the dystrophin gene, which results in absent or defective dystrophin protein, leading to progressive and irreversible muscle function loss.

Evidence for Clobazam Monotherapy Use in Focal, Generalized Seizures Reviewed

Evidence for Clobazam Monotherapy Use in Focal, Generalized Seizures Reviewed

By

The safety and efficacy of clobazam monotherapy in patients with new-onset focal or generalized seizures was investigated in a new Cochrane systematic review.

Vigadrone Available for Refractory Complex Partial Seizures, Infantile Spasms

Vigadrone Available for Refractory Complex Partial Seizures, Infantile Spasms

By

The FDA has approved an abbreviated New Drug Application for Vigadrone, the generic alternative to Sabril powder for oral solution.

Fremanezumab Chronic Cluster Headache Study Discontinued

Fremanezumab Chronic Cluster Headache Study Discontinued

By

Teva has decided to discontinue part of the ENFORCE Phase 3 clinical development program for fremanezumab.

More Articles by Diana Ernst, RPh

Sign Up for Free e-newsletters



CME Focus